USPTO Art Unit 1658 Prosecution Statistics

Art Unit Information

Art Unit: 1658
Group: 1650
Tech Center: 1600
Total Cases: 5,073
Last Active: October 2024

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18917707ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEOctober 2024February 2025Allow410NoNo
18912061INSECT NEUROPEPTIDES 6October 2024May 2025Allow711YesNo
18903864THERAPEUTIC POLYPEPTIDEOctober 2024April 2025Allow601NoNo
18893357INCRETIN ANALOGS AND USES THEREOFSeptember 2024March 2025Allow611NoNo
18820792SEMAGLUTIDE IN MEDICAL THERAPYAugust 2024February 2025Allow520NoNo
18806394PROCESSES AND INTERMEDIATES FOR PREPARING TIRZEPATIDEAugust 2024February 2025Allow601NoNo
18774846COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERSJuly 2024January 2025Allow711NoNo
18724136IL-4 DERIVED PEPTIDE FRAGMENTS FOR USE IN THE TREATMENT OF DIABETIC NEPHROPATHYJune 2024June 2025Allow1220NoNo
18751723NPY2 RECEPTOR AGONISTSJune 2024May 2025Allow1101NoNo
18736608SEMAGLUTIDE IN MEDICAL THERAPYJune 2024January 2025Abandon700NoNo
18666750STAPLED AND SPECIFICALLY TARGETED ANTIMICROBIAL PEPTIDEMay 2024November 2024Allow611NoNo
18660504NOVEL PEPTIDESMay 2024August 2024Allow300NoNo
18650574ANTI-AGING STURGEON ROE TETRAPEPTIDE AND PREPARATION METHOD AND APPLICATION THEREOFApril 2024April 2025Allow1111YesNo
18637124ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEApril 2024March 2025Allow1110NoNo
18632799COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGSApril 2024February 2025Allow1001YesNo
18626600SYSTEMS AND METHODS FOR TREATMENT OF HEARING USING DIHEXAApril 2024March 2025Allow1110NoNo
18616600METHODS FOR TREATING CANCERS USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONSMarch 2024January 2025Allow1000YesNo
18612612HUMAN COLLAGEN 17-TYPE POLYPEPTIDE, PRODUCTION METHOD THEREFOR AND USE THEREOFMarch 2024June 2025Allow1411NoNo
18612627HUMAN COLLAGEN 17-TYPE POLYPEPTIDE, PRODUCTION METHOD THEREFOR AND USE THEREOFMarch 2024June 2025Allow1411NoNo
18600947EGG WHITE PROTEIN ANTI-INFLAMMATORY PEPTIDE AND APPLICATION THEREOFMarch 2024October 2024Allow711YesNo
18591918ACTIVIN RECEPTOR TYPE IIB VARIANTS AND USES THEREOFFebruary 2024May 2025Allow1501YesNo
18589590CYCLIC PEPTIDE ANTIVIRAL AGENTS AND METHODS USING SAMEFebruary 2024May 2025Allow1501YesNo
18590636STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTIONFebruary 2024April 2025Allow1310YesNo
18582180HETERODIMERIC FC CYTOKINES AND USES THEREOFFebruary 2024August 2024Allow611NoNo
18581115STAPLED ANTIMICROBIAL PEPTIDEFebruary 2024November 2024Allow901YesNo
18444501Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and pharmaceutically acceptable salts of amylin analogs, and uses thereofFebruary 2024October 2024Allow801NoNo
18434731DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOFFebruary 2024December 2024Allow1110YesNo
18427270GLP-1 COMPOSITIONS AND USES THEREOFJanuary 2024September 2024Allow820YesNo
18424386HETEROTANDEM BICYCLIC PEPTIDE COMPLEXJanuary 2024March 2025Allow1300NoNo
18423020ANTI-KRAS-G12D T CELL RECEPTORSJanuary 2024April 2025Allow1511NoNo
18422878COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTORJanuary 2024June 2025Allow1711NoNo
18415952BIOLOGICAL ACTIVE PEPTIDE FOR IMPROVING ENZYME ACTIVITY OF ACE2 AND APPLICATION THEREOFJanuary 2024January 2025Allow1220NoNo
18414112MODIFIED ANTI-INFLAMMATORY PROTEINS AND METHOD OF USEJanuary 2024June 2025Allow1710YesNo
18405731IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCERJanuary 2024April 2025Abandon1510NoNo
18390354MOLECULAR GUIDE SYSTEM PEPTIDES AND USES THEREOFDecember 2023June 2025Allow1821NoNo
18541682NOVEL INSULIN ANALOGUES AND USES THEREOFDecember 2023August 2024Allow820NoNo
18540219GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USEDecember 2023November 2024Allow1112YesNo
18568888SURFACE LAYER PROTEIN A (SLPA) AS A THERAPEUTIC AGENT FOR THE TREATMENT OF INFLAMMATORY DISEASESDecember 2023May 2024Allow500YesNo
18568525Peptide compounds targeting PD-1 receptor as well as preparation and applications thereofDecember 2023January 2025Allow1411NoNo
18531607CYCLIC PEPTIDOMIMETIC FOR THE TREATMENT OF NEUROLOGICAL DISORDERSDecember 2023December 2024Allow1310NoNo
18518227PREPARATION METHOD AND APPLICATION OF HIGH-PURITY PLANT-DERIVED RECOMBINANT HUMAN SERUM ALBUMINNovember 2023September 2024Allow1021NoNo
18518000METHODS AND COMPOSITIONS FOR DELIVERY OF VIRAL VECTORS ACROSS THE BLOOD-BRAIN BARRIERNovember 2023December 2024Allow1300NoNo
18512512AMYLIN RECEPTOR AGONISTSNovember 2023August 2024Allow901NoNo
18513026NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENTNovember 2023April 2025Abandon1710NoNo
18504561LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATESNovember 2023March 2025Allow1610YesNo
18502536COMPOSITIONS AND METHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITYNovember 2023April 2025Abandon1701NoNo
18386971PEPTIDE INHIBITORS OF NF KAPPA B AND USE THEREOF IN TREATMENT OF COVID-19 AND INFLAMMATORY DISEASESNovember 2023June 2025Abandon1911NoNo
18501864A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTSNovember 2023June 2025Abandon1901NoNo
18385946CNP COMPOUNDSNovember 2023May 2024Allow601YesNo
18385771TREATMENT OF HPV INFECTIONOctober 2023November 2024Abandon1310NoNo
18496597METHOD FOR ADJUSTING A PARENTERAL SUPPORT (PS) VOLUME IN A HUMAN SUBJECTOctober 2023January 2025Abandon1521NoNo
18494883FACTOR H VARIANTS FOR TREATMENT OF DISEASEOctober 2023October 2024Allow1221YesNo
18494638PEPTIDE THERAPEUTICS FOR INCREASING LUNG CELL VIABILITYOctober 2023December 2024Abandon1430YesNo
18494535CLOTTING FACTOR PREPARATIONS FOR DELIVERY INTO TISSUE OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICEOctober 2023September 2024Allow1110YesNo
18383167SEMAGLUTIDE FOR USE IN MEDICINEOctober 2023April 2025Abandon1710NoNo
18492982VSIG8-BASED CHIMERIC PROTEINSOctober 2023May 2025Abandon1901NoNo
18492006INSECT NEUROPEPTIDES 3October 2023September 2024Allow1111NoNo
18492058INSECT NEUROPEPTIDES 4October 2023March 2025Allow1721YesNo
18492050INSECT NEUROPEPTIDES 8October 2023October 2024Allow1212YesNo
18491957INSECT NEUROPEPTIDES 1October 2023February 2025Allow1621YesNo
18492076INSECT NEUROPEPTIDES 9October 2023October 2024Allow1221YesNo
18491976INSECT NEUROPEPTIDES 6October 2023July 2024Allow911YesNo
18491750Interference Peptides As Inhibitors Of Interactions Related To Ampar EndocytosisOctober 2023January 2025Abandon1501NoNo
18486310ULTRA-LONG ACTING INSULIN-FC FUSION PROTEIN AND METHODS OF USEOctober 2023October 2024Allow1200YesNo
18483343METHOD FOR PROTEIN NANOWIRE SYNTHESIS AND TUNABLE CONTROL OF NANOWIRE LENGTHOctober 2023April 2025Allow1820YesNo
18483108POLYPEPTIDES AND MEDICAL USES THEREOFOctober 2023June 2024Allow901NoNo
18481170METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERSOctober 2023September 2024Allow1210YesNo
18375639CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPYOctober 2023December 2024Abandon1410NoNo
18479445PRODRUG COMPRISING A DRUG LINKER CONJUGATEOctober 2023December 2024Abandon1501NoNo
18374864MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOFSeptember 2023April 2025Abandon1811NoNo
18474456POLYPEPTIDE INHIBITOR OF DE NOVO LIPOGENESIS IN CANCER CELLSSeptember 2023June 2024Allow901YesNo
18473846MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORSSeptember 2023June 2025Allow2121NoNo
18473627BROWN FAT-SELECTIVE ADIPOKINESSeptember 2023April 2025Allow1821YesNo
18473073PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATIONSeptember 2023September 2024Allow1211NoNo
18471220REGENERATIVE POLYPEPTIDES AND USES THEREOFSeptember 2023December 2024Abandon1521NoNo
18467206FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNA AND IFNB) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOFSeptember 2023August 2024Allow1101NoNo
18466548PEPTIDE COMPOUNDS AND METHODS OF USESeptember 2023April 2025Abandon1911NoNo
18464295TOPICAL COMPOSITIONS COMPRISING PEA PROTEINS AND POLYPHENOLSSeptember 2023April 2025Abandon1910NoNo
18459998METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACIDSeptember 2023December 2024Allow1611YesNo
18460300PEPTIDE-COMPOUND CYCLIZATION METHODSeptember 2023March 2025Allow1911NoNo
18240295PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPYAugust 2023November 2024Allow1510NoNo
18457482GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS AND USES THEREOFAugust 2023May 2024Allow800YesNo
18454780METHODS AND COMPOSITIONS FOR EGG WHITE PROTEIN PRODUCTIONAugust 2023March 2025Abandon1921YesNo
18453807INHIBITORS OF NF KAPPA-B ACTIVITY FOR TREATMENT OF DISEASES AND DISORDERSAugust 2023February 2025Allow1811NoNo
18450524RAGE PROTEINS FOR THE TREATMENT OF FIBROSIS AND DNA DAMAGE MEDIATED DISEASESAugust 2023June 2025Abandon2211YesNo
18448650METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONSAugust 2023February 2024Allow601YesNo
18231483CRYSTALLINE SALT FORMS OF BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2August 2023June 2024Allow1000YesNo
18366130TREATMENT OF PEDIATRIC TYPE 2 DIABETES MELLITUS PATIENTSAugust 2023March 2025Abandon1911NoNo
18366558CONJUGATED HEPCIDIN MIMETICSAugust 2023October 2024Allow1401NoNo
18363999DAPTOMYCIN FORMULATIONSAugust 2023March 2024Allow700YesNo
18363448MATERIALS AND METHODS FOR IMPROVING GASTROINTESTINAL FUNCTIONAugust 2023October 2024Allow1511NoNo
18227782COMPOUND WITH ANALGESIC EFFECT FOR USE IN PREVENTION AND TREATMENT OF PAINJuly 2023July 2024Allow1201YesNo
18274952COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERSJuly 2023May 2025Allow2140NoNo
18360773COMPOSITION FOR IMPROVING MILD COGNITIVE IMPAIRMENT AND METHOD FOR IMPROVING MILD COGNITIVE IMPAIRMENTJuly 2023November 2024Abandon1610NoNo
18355539CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOFJuly 2023March 2025Allow2001YesNo
18272674Compositions And Methods of Synthesizing Shape Shifting Cyclic Peptides (Sscp) And Their Use in The Identification of Novel Therapeutic CompoundsJuly 2023November 2024Abandon1601YesNo
18352637UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAMEJuly 2023January 2025Abandon1810NoNo
18351169GHRH OR ANALOGUES THEREOF FOR USE IN TREATMENT OF HEPATIC DISEASEJuly 2023December 2024Allow1710NoNo
18350543IL-7R-ALPHA-GAMMA BINDING COMPOUNDSJuly 2023February 2024Allow711NoNo
18349855FLUORESCENT COMPOUND COMPRISING A FLUOROPHORE CONJUGATED TO A pH-TRIGGERED POLYPEPTIDEJuly 2023January 2025Allow1810NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1658.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
80
Examiner Affirmed
54
(67.5%)
Examiner Reversed
26
(32.5%)
Reversal Percentile
50.3%
Higher than average

What This Means

With a 32.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
406
Allowed After Appeal Filing
76
(18.7%)
Not Allowed After Appeal Filing
330
(81.3%)
Filing Benefit Percentile
3.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1658 - Prosecution Statistics Summary

Executive Summary

Art Unit 1658 is part of Group 1650 in Technology Center 1600. This art unit has examined 5,073 patent applications in our dataset, with an overall allowance rate of 63.3%. Applications typically reach final disposition in approximately 29 months.

Comparative Analysis

Art Unit 1658's allowance rate of 63.3% places it in the 18% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1658 receive an average of 1.88 office actions before reaching final disposition (in the 55% percentile). The median prosecution time is 29 months (in the 47% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.